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Abstract 
Background: Studies show that educational interventions improve glycemic control in patients with diabetes mel-
litus (DM), reducing the occurrence of complications associated with the disease.
Objectives: To evaluate the effects of a mobile DM consultancy on clinical and laboratory parameters, disease knowl-
edge, and quality of life in patients with type 2 DM (T2DM) at a primary health care network in Brazil.
Methods: Randomized clinical trial conducted in a city in southern Brazil with 52 patients with T2DM receiving care 
at a primary health care setting. The intervention lasted for 6 months and consisted of a follow-up with an endocri-
nologist (five meetings), treatment adjustment based on clinical evaluation and laboratory tests, and educational 
activities with conversation maps in DM. The statistical analysis included comparison and association tests, consider-
ing p values ≤0.05 as statistically significant.
Results: The mean age of the patients was 63.8 years. Most participants were female (63.5 %), had low educational 
level (59.6 %) and family history of T2DM (71.2 %), used only oral hypoglycemic agents to manage their DM (73.2 %), 
presented unfavorable anthropometric and laboratory parameters, a high or medium risk of complications (84.6 %), 
and inadequate glycemic control (67.3 %; with 71 % of the high-risk patients presenting a HbA1c level >9 %). Adjust-
ment in pharmacological treatment was required in 63.5 % of the patients. After the intervention, we observed a 
significant 0.46 % decrease in mean HbA1c level (p = 0.0218), particularly among individuals with inadequate gly-
cemic control (0.71 %; p = 0.0136). Additionally, there was an increase in disease knowledge scores and a significant 
decrease in mean body mass index, waist circumference, and disease impact scores.
Conclusion: The intervention improved glycemic control and disease knowledge, reduced the values of body mass 
index and waist circumference, and the impact of the disease on patients’ lives. This indicates that care and educa-
tional measures improve the experience of the patients with DM and control of the disease.
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Background
Diabetes mellitus (DM) is a disease with strong social 
impact, associated with high morbidity and mortal-
ity rates that result from long-term microvascular and 
macrovascular complications [1]. The prevalence of DM 
is increasing worldwide, despite international efforts 
to control the disease. Data published by the Interna-
tional Diabetes Federation (IDF) show an estimated 
8.8  % prevalence of DM in individuals between 20 and 
79 years of age (415 million individuals) and point to an 
estimated 642 million patients affected with the disease 
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in 2040, a 10.4 % prevalence [2]. In Brazil, it is estimated 
that the number of adult patients with DM increased 
from 4.3 million in 2000 [3] to 14.3 million in 2015, and 
is expected to increase to 23.2 million in 2040. This will 
project the country to occupy the 4th position in number 
of patients with DM worldwide [2].
Two important multicenter studies, the Diabetes Con-
trol and Complications Trial (DCCT) and the United 
Kingdom Prospective Diabetes Study (UKPDS), have 
demonstrated benefits with strict blood glucose control. 
The DCCT [4], conducted with individuals with type 1 
DM (T1DM), has shown that the maintenance of blood 
glucose levels close to normal values with intensive insu-
lin therapy reduces the incidence and severity of chronic 
complications. The UKPDS [5], in turn, has demon-
strated that improved glycemic control may reduce the 
risk of development of chronic complications in type 2 
DM (T2DM).
In Brazil, despite the available therapeutic options, 
efforts of teams specialized in the treatment of DM [6], 
and government initiatives (such as a system of registra-
tion and follow-up of hypertensive and diabetic patients 
[7], instituted in primary health care), the glycemic 
control of diabetic patients is worse than expected. In a 
Brazilian multicenter study involving 6671 adults with 
T1DM and T2DM [8], 76 % of the patients had an inad-
equate glycemic control (HbA1c ≥7  %). This rate was 
90 % among patients with T1DM and 73 % in those with 
T2DM. In another study conducted in Goiânia (Goiás) 
[9] including only individuals with T1DM, the rate of 
inadequate control was 81.7 %. Poor glycemic control is 
also an international problem. A study conducted in the 
U.S., for example, has shown that approximately 50 % of 
the individuals with DM in that country have poor glyce-
mic control [10].
Education in DM increases patients’ self-care, improv-
ing their glycemic control and knowledge of the disease 
[6]. Evidence suggests that educational programs con-
ducted in groups improve cost-effectiveness, particularly 
in adults with T2DM [11, 12]. In patients with T1DM, 
the improvement is mainly observed in the psychoso-
cial sphere [13]. In Brazil, a randomized, prospective, 
multicenter study including individuals with T1DM and 
T2DM, known as Projeto DOCE® (Diabetes Aiming Con-
trol and Education, Diabetes Objetivando Controle e Edu-
cação), developed by a multiprofessional team, showed 
significant improvement in blood glucose control, but no 
variation in quality of life scores [14–16].
Considering the imbalanced distribution of endocri-
nologists in Brazil, where most specialists (76.08  %) are 
concentrated in the country’s southeastern and southern 
areas [17], the current challenge is to provide better job 
opportunities and professional training continuity in less 
served regions, allowing a more balanced distribution of 
specialists operating both in public and private health 
sectors, and in small and large urban centers.
Considering the precariousness of the glycemic control 
in patients with DM worldwide, and the direct impli-
cations that poor glycemic control imposes on the risk 
of development of complications and health expenses, 
the aim of this study was to evaluate the effects of the 
action of a mobile consultancy unit specialized in DM 
on clinical and laboratory parameters, as well as on the 
degree of knowledge of and satisfaction with the disease 
in patients with T2DM in a primary health care network 
in Brazil.
Methods
Delineation and population
This is a randomized, non-placebo-controlled clinical 
trial (Fig. 1) with individuals with T2DM, developed in a 
primary care setting in the city of Maringá (Paraná) [18], 
southern Brazil, between October, 2014, and August, 
2015. The city has 30 primary health units (Unidades 
Básicas de Saúde, UBS) and the study was conducted in 
nine of these units. To select the UBS for inclusion in the 
study, we took into account the division of the city into 
three homogeneous areas according to the economical 
resources and demographic structure of the population 
[19]: G1 (more favorable, six UBS), G2 (intermediate, 
four UBS), and G3 (less favorable, 20 UBS). The num-
ber of UBS and patients per UBS was proportional to the 
Evaluated for eligibility (n= 2573)
Allocated to intervention (n= 80)
ġœŦŤŦŪŷŦťġŵũŦġŢŭŭŰŤŢŵŦťġintervention (n= 61)
ġŅŪťġůŰŵġųŦŤŦŪŷŦġŵũŦġŢŭŭŰŤŢŵŦťġŪůŵŦųŷŦůŵŪŰůĻ
• Due to discontinuation (n=17)
• For not fulfilling the inclusion criteria 
(n=2)
Loss of follow-up (lack of participation in all 
study stages) (n=9)
Analyzed (n=52)
Allocation
Analysis
Follow-up
Randomized (n=102)
Recruitment
* CONSORT Consolidated Standards of Reporting Trials
Fig. 1 Study flow diagram
Page 3 of 11Eik Filho et al. Diabetol Metab Syndr  (2016) 8:56 
number of individuals with DM registered in each area 
(two UBS in group G1, two in group G2, and five in group 
G3). The total number of eligible individuals in all nine 
UBS was 2573.
We adopted the following inclusion criteria: diagnosis 
of T2DM, age between 18 and 80  years, and interest in 
and availability to participate in the activities of the study. 
The patients were selected randomly and proportionately 
to the population of individuals with T2DM in each of 
the nine UBS. The participation was entirely voluntary, 
and the selected individuals could be replaced by the next 
individual on the list for a maximum of three times. We 
excluded individuals who presented important mental 
disorder, severe associated diseases, substantial decrease 
in visual acuity, and impaired ambulation. Of 80 con-
tacted patients, 61 agreed to participate in the study and 
52 participated in all stages of the study.
Data collection
The data were collected at each UBS at three moments: 
initial visit (V1; before the intervention, during the selec-
tion of the individual for the study), intermediate visit 
(V4; 3  months after the first intervention), and final 
visit (V5; 6 months later). In all meetings, we consulted 
the electronic records of the patients to analyze the data 
related to their clinical condition and treatment regimen, 
and verify their anthropometric data and serum HbA1c 
results. Levels of serum HbA1c were determined with 
an Ames analyzer (Bayer Diagnostics, DCA 2000). The 
normal range for HbA1c values determined with this 
analyzer is between 4.2 and 6.5  % (mean 5.0 ±  0.35  %, 
95 % confidence interval 4.3–5.7 %) [20, 21]. The correla-
tion coefficient of HbA1c values obtained with the Ames 
analyzer compared with values obtained by high-perfor-
mance liquid chromatography (HPLC) is 0.95 [22]. The 
other laboratory tests and the questionnaires were only 
performed/applied at V1 and V5.
To collect the data, we applied the following three 
questionnaires
(1) Identification questionnaire: sociodemographic 
characteristics and lifestyle habits (sex, age, skin color, 
educational level, family income, smoking, alcohol 
abuse, and practice of physical activity), anthropomet-
ric data (weight [kg], height [m], BMI [kg/m2], waist 
circumference [WC; cm], hip circumference [HC; cm], 
WC/HC ratio, and blood pressure [BP; mmHg]), clini-
cal data (type of treatment, disease duration, family his-
tory, comorbidities, metabolic control, and degree of risk 
of complications), and laboratory data (complete blood 
count, fasting blood glucose, HbA1c, creatinine, potas-
sium, lipid profile, alanine aminotransferase [ALT] and 
aspartate aminotransferase [AST]), TSH, urinalysis, and 
microalbuminuria. All laboratory tests were performed 
by the Health Department of Maringá (Paraná), and only 
those tests performed up to 6 months before the begin-
ning of the study were included in the analysis.
We considered as smokers those individuals who were 
current smokers, independent of the number of ciga-
rettes they smoked. Alcohol abuse was defined as alco-
hol ingestion on a single occasion of 60 g or more of in 
the previous 30  days [23]. We considered as sedentary 
those individuals who presented a caloric expenditure 
≤1.5 kcal/kg/h [24]. The reference values adopted for the 
anthropometric parameters and risk factors were: BMI: 
<18.5, low weight; 18.5–24.9, normal weight; 25–29.9, 
overweight; 30–34.9, grade I obesity, 35–39.9, grade II 
obesity; ≥40, grade III obesity; WC: men: ≤94, normal 
and ≥102, increased; women: ≤80, normal and ≥88, 
increased; WC/HC: men: ≤0.9, normal; women: ≤0.85, 
normal; abnormal BP: ≥140/90 [25, 26]. The metabolic 
control was classified as good (HbA1c ≤7  %), regular 
(HbA1c >7 % and ≤9 %), or poor (HbA1c >9 %) [27].
We also considered individuals with HbA1c level >7 % 
(which includes those with regular and poor control) as 
having inadequate glycemic control. The risk of compli-
cations was graded based on criteria from the program 
Qualification of Primary Health Care (Qualificação da 
Atenção Primária à Saúde, APSUS), adopted by primary 
care professionals in the state of Paraná [28]. Regarding 
the DM [29], the patients were classified into three lev-
els: low risk (fasting blood glucose or glucose intolerance 
determined in the oral glucose overload test), medium 
risk (DM and adequate metabolic and BP controls, with-
out hospitalizations due to acute complications in the 
past 12  months, without chronic complications), high 
risk (DM and inadequate metabolic and BP control, or 
adequate metabolic and BP controls, but with hospitali-
zations due to acute complications in the past 12 months 
and/or presence of chronic complications).
(2) Questionnaire assessing DM knowledge: we applied 
the DKN-A (Diabetes Knowledge Scale Questionnaire), 
validated for the Brazilian population [30]. This question-
naire comprises 15 items related to DM knowledge (basic 
physiology, food groups and substitutions, management 
of DM in intercurrent events, and general principles of 
DM care) [30]. The responses are presented in a multi-
ple-choice scale and the total score ranges from 0 to 15 
points. Scores ≤7 indicate unsatisfactory knowledge, and 
scores ≥8 reflect satisfactory knowledge [31].
(3) Diabetes Quality of Life Measure-Brazil (DQOL-
BR), validated for the Brazilian population [32]: this 
questionnaire comprises 44 questions distributed in four 
domains, namely: satisfaction (15 questions), impact 
(18 questions), social/vocational concerns (seven ques-
tions), and concerns related to the DM (four questions). 
Answers are given on a Likert-type scale of five points. 
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In the overall score or in the score for each domain, the 
closer the result is to 1, the greater the satisfaction with 
the quality of life related to the disease.
Intervention
The intervention was carried out exclusively by the prin-
cipal investigator, and occurred in three phases that 
included (1) a follow-up by an endocrinologist with 
adjustment of pharmacological and non-pharmacological 
treatments based on clinical and laboratory evaluation, 
and (2) educational activities with the application of con-
versation maps (CMs) in DM. The CMs were developed 
by the American health education company Healthy 
Interactions in partnership with a pharmaceutical com-
pany [33]. The maps feature an interactive content and 
are presented by a facilitator trained by a specialized 
instructor. In all, there are seven 91.4 × 138.6 cm maps 
that present varying aspects of the disease, such as eti-
opathogenesis, pathophysiology, diet, physical activity, 
types of treatment and monitoring, as well as control and 
complications associated with the disease. In the pre-
sent study, we used three CMs (numbers 1 and 2), enti-
tled, respectively: “How the body and diabetes work” and 
“Healthy diet and physical activity” which were presented 
at two meetings held in the same week—visits 2 (V2) 
and 3 (V3). CM number 3 (“Drug treatment and blood 
glucose monitoring”) was applied 3  months later, at the 
fourth visit (V4). The sessions with CMs lasted two to 3 h 
and occurred at the UBS in groups of 5–10 individuals in 
the meetings V2, V3 and V4, which had a total duration 
of approximately 4 h.
The adjustment of the non-pharmacological and phar-
macological therapies was performed according to the 
guidelines of the Brazilian Diabetes Society (Sociedade 
Brasileira de Diabetes) [6], starting preferably at initial 
meeting (V1) before sessions with the conversation maps, 
but were made occasional treatment adjustments mainly 
in V4 and V5, due to the availability of additional sched-
ules to individualize all the proposed activities.
The endocrinologist in charge of the study was author-
ized by the Municipal Health Department and consented 
by the UBS doctors to manipulate the medical records, 
adjust treatment, and request laboratory tests when nec-
essary. In the last visit (V5), the patients were encouraged 
to maintain the recommendations proposed in the study 
and continue to adhere to the UBS educational programs. 
The health professionals at the UBS were informed about 
the results obtained in the study and the availability of 
the endocrinologist for future contacts.
Statistical analysis
Quantitative variables were assessed for normality with 
the Shapiro–Wilk test. Descriptive variables with a 
significance level of 5 % in the test are presented as mean 
and standard deviation. Variables without normal dis-
tribution are presented as median and quartiles range 
(percentiles 25 and 75 ‰). To compare mean and median 
values between V1 and V5, we used paired Student’s t 
test and Wilcoxon test, respectively, according to the 
distribution of each variable, considering a significance 
level of 0.05. To evaluate the homogeneity and similar-
ity of all three groups, we used Chi square, Fisher’s exact, 
and Kruskal–Wallis tests, according to each variable ana-
lyzed. All analyses were performed with the software R 
(The R Foundation for Statistical Computing, Vienna, 
Austria).
Ethics
The study was conducted according to national and inter-
national ethics standards for research involving human 
subjects (protocol CAAE: 25897314.7.0000.0104).
Results
Sociodemographic and clinical data
Table  1 shows the general characteristics of the study 
participants according to assignment group, consumer 
class, and demographic structure. We observed no sig-
nificant differences in general characteristics among the 
groups, except for family history (DM), and WC/HC val-
ues in women, thus enabling the groups to be analyzed 
together. As shown in Table 1, of the 52 patients included 
in the study, most (63.5 %) were female, white (80.8 %), 
and had a low educational level (59.6 %). The mean age 
was 63.8  years (38–80  years), and the most frequent 
age group was that of individuals aged 60 years or more 
(69.2 %). The monthly family income of most participants 
(90.5  %) varied between two and five minimum wages 
(approximately 500–1500 US Dollars).
As for lifestyle habits (Table 1) only one individual was 
a smoker, most participants (96.2 %) did not abuse alco-
hol, and less than half of the individuals (46.1  %) prac-
ticed mild or moderate physical activity.
Regarding clinical variables, we observed that the 
median disease duration was 9  years, ranging from 
1–50 years. Most patients had regular or poor blood glu-
cose control (67.3 %), were classified as having a high or 
medium risk of complication (84.6  %), reported having 
family history of T2DM (71.2 %), and were only treated 
with oral antidiabetic agents (73.2 %), mainly metformin 
at a dose between 500 and 2550  mg/day, sulphony-
lureas (glibenclamide 5–20  mg/day or gliclazide MR 
30–120 mg/day). Three patients (5.8 %) used vildagliptin 
100  mg/day, and one patient used pioglitazone 30  mg/
day.
The most frequent diseases associated with DM were 
hypertension (75  %), obesity (46.1  %), dyslipidemia 
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(36.5 %), and hypothyroidism (13.46 %). It is noteworthy 
that of the 39 patients with associated hypertension at the 
initial evaluation, 15.4 % had a BP level ≥140/90 mmHg 
(data not shown).
As for the anthropometric indices, the mean BMI, WC, 
and the WC/HC ratio in both genders showed evidence 
of an association between overweight and DM.
The results of laboratory tests showed anemia in four 
patients (7.7  %) and absence of significant changes in 
leukocyte count, platelets, ALT, AST, potassium, lipid 
profile, TSH, and urinalysis. The combined analysis of 
creatinine and microalbuminuria showed the occurrence 
of diabetic nephropathy in 17.3 % of the patients.
The mean serum HbA1c level was 8.91 %. The glycemic 
control was good in 17 patients (32.7  %), regular in 16 
patients (30.8 %), and poor in 19 patients (36.5 %). Thus, 
35 patients (67.3 %) presented inadequate glycemic con-
trol. The median serum HbA1c level was 7.75  % (6.95–
10.1  %). A total of 50  % of the individuals presented an 
HbA1c level between 7.0 and 10.1, and 25 % above 10.1 %.
Knowledge about DM and quality of life related to the 
disease
In relation to the knowledge about DM, we observed that 
the median score was 8.5, and only a little more than half 
of the patients (51.9 %) achieved a score ≥8. As for sat-
isfaction with life related to the disease, we found that 
overall and for each of the domains, the scores were near 
2, with the exception of the domain social/vocational 
concerns, in which the score was close to 1.
Table 1 General characteristics of the patients at the beginning of the study (V1)
NP non-pharmacological treatment; OM oral medications; OM/I oral medications and insulin; BMI body mass index; WC waist circumference; WC/HC waist 
circumference/hip circumference ratio
* Chi square test
** Fisher exact test
*** Kruskal–Wallis test
Variables Group 1 Group 2 Group 3 Total p value
Gender Female 9 (60.0) 12 (85.7) 12 (52.2) 33 (63.5) 0.110*
Male 6 (40.0) 2 (14.3) 11 (47.8) 19 (36.5)
Age <60 years 2 (13.3) 3 (21.4) 11 (47.8) 16 (30.8) 0.068**
≥60 years 13 (86.7) 11 (78.6) 12 (52.2) 36 (69.2)
Race White 14 (93.3) 10 (71.5) 18 (78.3) 42 (80.8) 0.326**
Non white 1 (6.7) 4 (28.6) 5 (21.7) 10 (19.2)
Educational level ≤8 years 9 (60.0) 11 (78.6) 13 (56.5) 33 (63.4) 0.380*
>8 years 6 (40.0) 3 (21.4) 10 (43.5) 19 (36.6)
Smoking No 14 (93.3) 14 (100.0) 23 (100) 51 (98.1) 0.557**
Yes 1 (6.7) 0 0 1 (1.9)
Alcoholism No 13 (86.7) 14 (100.0) 23 (100) 50 (96.2) 0.148**
Yes 2 (13.3) 0 0 2 (3.8)
Physical Activity Mild/moderate 7 (46.7) 7 (50.0) 10 (43.5) 34 (46.1) 0.927*
Sedentary 8 (53.3) 7 (50.0) 13 (56.5) 28 (53.9)
Treatment NP 0 0 2 (8.7 %) 2 (3.8 %) 0.179**
OM 9 (60 %) 12 (85.7 %) 17 (74 %) 38 (73.2 %)
OM/I 6 (40.0 %) 2 (14.3 %) 4 (17.3 %) 12 (23.0 %)
DM duration (years) 10 (8, 23.5) 11 (3.5, 19.3) 6 (3, 11) 9 (4, 15) 0.083***
BMI 30.37 ± 6.2 30.32 ± 4.5 29.67 ± 3.9 30.05 ± 4.7 0.470***
WC Female 102.7 ± 14.6 98.4 ± 9.6 104.62 ± 10.3 101.8 ± 11.3 0.356***
Male 109.4 ± 12.2 117 ± 12.0 103.1 ± 10.0 106.6 ± 11.3 0.320***
WC/HC Female 0.94 ± 0.03 0.93 ± 0.03 0.99 ± 0.03 0.95 ± 0.04 0.001***
Male 0.99 ± 0.04 1.04 ± 0.04 0.99 ± 0.05 0.99 ± 0.05 0.358***
Family No 8 (53.3) 4 (28.6) 3 (13.0) 15 (28.8) 0.027**
History (DM) Yes 7 (46.7) 10 (71.4) 20 (87.0) 37 (71.2)
Complication Low 2 (13.3) 3 (21.4) 3 (13.0) 8 (15.4)
Risk Medium 3 (20.0) 6 (42.9) 11 (47.9) 20 (38.4) 0.371**
High 10 (66.7) 5 (35.7) 9 (39.1) 24 (46.2)
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Evaluation of the intervention
Clinical and laboratory evaluation pointed out to a 
requirement for adjustment in pharmacological treat-
ment in 33 patients (63.5  %). In eight of these patients, 
the insulin dose was adjusted, in five cases insulin was 
started, and in 28 patients, either the insulin dose was 
adjusted, or the oral antidiabetic class was modified alone 
or in combination with the insulin adjustment. It is note-
worthy that in most cases we maintained those medica-
tions available without cost in the public health network. 
Only four individuals were able to afford other classes 
of oral antidiabetics not freely available (pioglitazone 
30 mg/day, linagliptin 5 mg/day, and dapagliflozin 10 mg/
day).
We observed a mean reduction of 0.69 % in HbA1c lev-
els between V1 and V4 (p = 0.0003) and 0.46 % between 
V1 and V5 (p  =  0.0219) (Fig.  2). When we considered 
only those patients with inadequate glycemic control 
(67.3 %), the improvement in HbA1c was more substan-
tial (Fig. 3), both from V1 to V4 (−1.07 %, p = 0.0001), as 
well as from V1 to V5 (−0.71 %, p = 0.0136).
The mean HbA1c level in individuals who required 
adjustments in their pharmacological treatment 
decreased from 9.61 to 9.01  %, a reduction of 0.6  % 
in 6  months of follow-up (p  =  0.445). In the group of 
patients without requirement of pharmacological adjust-
ment (36.5 %, n = 19), the mean HbA1c level decreased 
from 7.69 to 7.5 %, a reduction of 0.19 % (p = 0.9883).
In Table 2, we present a comparison of the initial and 
final values of the anthropometric variables and some 
laboratory tests according to the glycemic control. There 
was a statistically significant BMI reduction in individu-
als with good glycemic control at the beginning of the 
study, and a reduction in WC values in those with good 
and regular glycemic control at baseline.
As for the assessment of BP, the percentage of hyper-
tensive individuals who presented a BP ≥140/90 mmHg 
decreased from 15.4 to 5.8 %.
Regarding the subjective evaluation of knowledge 
about the disease and its impact on the lives of indi-
viduals with T2DM, Table 3 shows a comparison of the 
results obtained with the application of the question-
naires DKN-A and DQOL-BR between V1 and V5, 
according to the quality of the glycemic control in the 
beginning of the study. Considering the knowledge about 
the disease, the median score increased from 8.5 (5.5, 
10.5) to 9.0 (7.00, 11.0) and the proportion of individuals 
who achieved a score greater than or equal to 8 increased 
from 51.9 to 65.4 %. We observed a significant improve-
ment in disease knowledge level among individuals who 
at the beginning of the study had good glycemic control. 
As for the DQOL-BR questionnaire, we observed a sig-
nificant reduction (p < 0.05) in the total scores and in the 
V1 V4 V5
6
8
10
12
14
H
ba
1c
 (%
)
Wilcoxon test for paired samples
- V1 - V4 (p = 0.0003)
- V1 - V5 (p = 0.0219)
Fig. 2 Box plot of HbA1c levels before and after the intervention
Fig. 3 Box plot of HbA1c levels before and after the intervention in 
patients with inadequate glycemic control
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Table 2 Variation of anthropometric and laboratory data during the study
BMI body mass index; WC waist circumference; WC/HC waist circumference/hip circumference ratio
* Wilcoxon matched pairs test
** Paired t test
Variables Glycemic control (HbA1c) V1 V5 p value
Good 29 (28.2, 31.1) 28.9 (26.8, 30.3) 0.0157*
BMI Regular 31.1 (27.9, 33.5) 30.5 (28.1, 33.5) 0.1031*
Poor 28.1 (25.5, 32.4) 28.8 (25.5, 32.8) 0.8788*
Total 29.4 (27.5, 32.6) 29.05 (26.5, 32.7) 0.0296*
Good 103.58 ± 10.02 101.14 ± 10.06 0.0103**
AC Regular 105.06 ± 11.53 103.09 ± 10.60 0.0316**
Poor 102.28 ± 12.92 101.81 ± 11.46 0.5240**
Total 103.56 ± 11.44 101.99 ± 10.57 0.0014**
Good 0.98 ± 0.04 0.97 ± 0.04 0.6522**
AC/hip Regular 0.94 ± 0.04 0.94 ± 0.03 0.9280**
Poor 0.98 ± 0.05 0.98 ± 0.03 0.7626**
Total 0.97 ± 0.05 0.96 ± 0.04 0.6155**
Good 98 (91.5, 121.5) 111 (104, 125.5) 0.4558*
Fasting glycemia Regular 137.5 (124, 154) 128 (114.5, 168) 0.3453*
Poor 214 (136.5, 221.5) 180 (143, 200.5) 0.3486*
Total 135 (107.5, 160) 133 (112, 179.2) 0.4356*
Good 185.35 ± 26.80 184.26 ± 40.16 0.9662**
Total cholesterol Regular 172.71 ± 36.43 173.93 ± 37.93 0.5583**
Poor 173.27 ± 43.05 170.68 ± 42.84 0.5230**
Total 177.33 ± 32.84 175.83 ± 40.15 0.9454**
Good 44.5 (38, 62.5) 43 (39, 55) 0.2892*
HDL cholesterol Regular 38.5 (36, 43.5) 40 (36, 46.5) 0.7892*
Poor 37 (33.5, 44) 38 (34, 44.5) 0.9645*
Total 39 (36, 45.5) 40 (35, 47) 0.3917*
Good 115.17 ± 34.30 108.77 ± 38.57 0.4871**
LDL cholesterol Regular 105.38 ± 31.66 101.37 ± 32.21 0.9848**
Poor 99.48 ± 33.25 94.57 ± 33.97 0.5291**
Total 107.23 ± 32.84 101.13 ± 34.71 0.4285**
Good 24.5 (19.5, 28.5) 26.6 (19.2, 31.7) 0.7354*
VLDL cholesterol Regular 24.5 (21, 31.5) 24 (21.6, 36.1) 0.0546*
Poor 33 (22.1, 48) 32.5 (21.6, 42.25) 0.9658*
Total 26 (20, 32.5) 28.2 (20.9, 37.25) 0.3790*
Good 123.5 (98.25, 145) 133 (96,158.5) 0.7354*
Triglycerides Regular 124.5 (107, 161.5) 120 (108,180.5) 0.0691*
Poor 167 (112.5, 241) 170 (110, 226) 0.9658*
Total 131 (101, 165.5) 145 (106, 187) 0.4152*
Good 1 (0.7, 1.15) 0.85 (0.7, 1.12) 0.9999*
Creatinine Regular 0.9 (0.75, 0.98) 0.8 (0.75, 0.9) 0.9643*
Poor 0.9 (0.81, 0.97) 0.8 (0.6, 1.17) 0.7193*
Total 0.9 (0.7, 1) 0.8 (0.7, 1.1) 0.7567*
Good 12.2 (5.6, 45.7) 7.8 (5.6, 22.1) 0.4498*
Micro albuminuria Regular 8.4 (3.6, 20.5) 7.5 (5.0, 21.3) 0.4131*
Poor 9.9 (5.2, 17.2) 7.6 (5.5, 32.7) 0.4887*
Total 10.35 (4.8, 25.6) 7.6 (5.4, 28.5) 0.7229*
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impact domain scores in the group of patients with poor 
glycemic control, and in the satisfaction domain scores in 
individuals with good and poor control.
Discussion
The sociodemographic characteristics of the patients 
evaluated in this study are compatible with those 
expected for age- and gender-matched patients with 
T2DM. However, it is important to emphasize that the 
study cohort had an important characteristic: the fact 
that it had a single modifiable risk factor—lack of physi-
cal activity—since most individuals reported not smok-
ing nor abusing alcoholic beverages. This information 
is important for health professionals who need to find 
means to stimulate individuals with DM to practice phys-
ical activity.
Low family income, in turn, limits the implementation 
of appropriate treatment because it interferes with the 
choices of food and therapeutic plan, as discussed below.
As for the clinical characteristics, the mean val-
ues of BMI, WC, and WC/HC ratio associated with 
the increased prevalence of hypertension, obesity, and 
dyslipidemia, reflect the high frequency of diagnostic cri-
teria for metabolic syndrome, as expected for the sample 
of subjects in the study. A significant reduction in BMI 
and WC values in some groups of patients observed in 
this study suggest an improvement in treatment adher-
ence, with potential benefits to the glycemic control.
The high proportion of individuals classified as having 
a high or medium risk for DM complications, associated 
with the fact that most of these individuals had poor gly-
cemic control, shows greater dependence from health 
professionals and higher treatment costs, more specifi-
cally with hospitalization, diagnostic tests, and treatment 
of complications. These figures reflect the current Brazil-
ian situation, where health expenditures related to DM 
in 2015 were estimated at 21 billion US Dollars [2]. We 
should emphasize that hospitalizations commonly reflect 
an inadequate DM control. In this sense, a study carried 
out in the state of Paraná showed an increasing tendency 
of hospitalization due to DM in men aged 50–59  years 
and in those older than 80 years [34].
The fact that most patients managed their DM with 
oral antidiabetic agents alone is within the expected 
Table 3 Scores of the questionnaires DQOL-BR and DKN-A at V1 and V5
* Paired Wilcoxon test
** Paired t test
Variables Glycemic control (HbA1c) V1 V5 p value
DKN-A Good 7.18 ± 3.27 8.62 ± 2.46 0.0296**
Regular 8.70 ± 2.43 8.50 ± 3.52 0.8309**
Poor 8.61 ± 3.59 9.55 ± 2.59 0.2791**
Total 7.90 ± 3.15 8.86 ± 2.73 0.1409**
Total DQOL-BR Good 2.10 ± 0.45 2.01 ± 0.47 0.4139*
Regular 2.09 ± 0.73 1.99 ± 0.52 0.5693*
Poor 2.55 ± 0.51 2.09 ± 0.43 0.0033*
Total 2.60 (2.1, 3.3) 2.20 (1.87, 2.43) 0.0003*
DQOL-BR satisfaction Good 2.46 (2.27, 2.73) 2.2 (2.2, 2.27) 0.0382*
Regular 2.2 (1.91, 2.67) 2.08 (1.63, 2.55) 0.3668*
Poor 3.26 (2.47, 3.56) 2.4 (2.12, 2.67) 0.0249*
Total 2.11 (1.75, 2.11) 2.1 (1.67, 2.3) 0.1656*
DQOL-BR impact Good 1.85 (1.72, 1.89) 2.08 (1.51, 2.2) 0.9000*
Regular 1.77 (1.51, 2.48) 2.17 (1.65, 2.44) 0.9687*
Poor 2.58 (1.89, 2.80) 2.10 (1.83, 2.41) 0.0201*
Total 1 (1, 1.57) 1.13 (1, 1.7) 0.4698*
DQOL-BR Social/Vocational concerns Good 1.14 (1.00, 1.57) 1.13 (1, 2.15) 0.3323*
Regular 1.00 (1.00, 1.03) 1.05 (1, 1.61) 0.0519*
Poor 1.21 (1.00, 1.81) 1.12 (1, 1.7) 0.8433*
Total 2.25 (1.75, 2.87) 1.75 (1.5, 2.37) 0.0459*
DQOL-BR concerns related to the DM Good 2.00 (1.31, 2.62) 1.87 (1.50, 2.25) 0.2829*
Regular 2.00 (1.50, 2.12) 1.75 (1.25, 2.25) 0.9044*
Poor 2.37 (2.00, 2.81) 2.25 (1.75, 2.50) 0.2551*
Total 2.30 ± 0.57 1.98 ± 0.44 0.0035*
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for the average disease duration observed in our study 
(9 years), which corresponds to a disease phase in which 
the individual still has a residual pancreatic secretory 
function [6]. However, the fact that a sizeable portion of 
patients required modification of their prescribed phar-
macological regimen reflects the high rates of poor glyce-
mic control observed in other studies conducted in Brazil 
[8, 9]. The requirement for insulin therapy or adjust-
ment in the insulin regimen may be pointing to inertia 
in medical therapy, because when the HbA1c values are 
maintained above 7 %, even with maximum doses of two 
oral antidiabetic agents, there is an increased risk of car-
diovascular complications [35]. The use of new classes of 
oral antidiabetic agents could probably help decrease the 
rates of poor glycemic control, but the high cost of these 
drugs makes their acquisition difficult by most patients 
receiving care at the public health system in Brazil, a fact 
that was confirmed in this study, since most patients had 
income between two and five minimum wages and only 
four patients had resources to change the class of the oral 
antidiabetic drug before starting an insulin regimen.
Among the participants of this study, the main risk fac-
tor for complications was poor glycemic control, which 
was the result of inadequate prescribed and/or imple-
mented pharmacological treatment, since more than 
half of the patients required treatment adjustment, and 
non-adherence to non-pharmacological treatment guide-
lines, including lifestyle habits such as nutrition, practice 
of physical activity, alcohol consumption, and smok-
ing. Health professionals may have a strong influence on 
how patients with DM perceive their disease and follow 
treatment recommendations. The patients, in turn, need 
to find means to make their actions result in effective 
lifestyle changes, and in a more forceful way, in weight 
control and loss in individuals with T2DM. Patients’ 
motivation and attitude fluctuate during treatment and 
are influenced by cognitive, motivational, and emotional 
factors, and may be stimulated by health professionals 
[36].
The benefits of group education for individuals with 
T2DM have been previously demonstrated [11, 12]. A 
study [37] has shown that education of individuals with 
T2DM with the CMs instrument [33] was more effec-
tive in groups than individually, with a 1.4  % reduction 
in HbA1c in the intervention group and 0.5 % in the con-
trol group, in addition to improvements in lipid profiles 
in both groups.
Despite our observations about improved DM learning 
in the group with good glycemic control and an increased 
percentage of individuals with scores ≥8, the ability of 
individuals with T2DM to understand and retain infor-
mation provided by health professionals in primary care 
[7] is still relatively low. In our evaluation of the level of 
satisfaction associated with DM, the scores were similar 
to those in a study carried out in Curitiba (Paraná) [32], 
which characterized a dissatisfaction with the disease. 
The comparison of the satisfaction level before and after 
the intervention showed a partial improvement in the 
total score and in the satisfaction and impact domains, 
but still hints a dissatisfaction with the DM.
Although the present study was unable to establish 
on an individual basis the effect of the pharmacologi-
cal adjustment or the application of the CMs, the fact 
that the percentage of individuals with scores ≥8.0 in 
the DKN-A increased after the intervention from 51.9 
to 65.4  % suggests an improvement in the participants’ 
knowledge about the disease after application of the 
CMs. However, it is important to reinforce that knowl-
edge alone may not be sufficient to change health behav-
iors, especially among men and older individuals (since 
studies have shown that women are more prone to 
behavioral changes) [38, 39]. Also, the use of messages 
and content more appropriate to the cultural standard of 
these individuals is recommended to promote changes in 
daily behaviors. In this regard, health professionals need 
to evaluate in their practices the degree of knowledge 
that the patients have about their disease, and the impact 
that the disease has on their lives, enabling a therapeutic 
plan more congruent with the condition of each patient.
In this study, the mean HbA1c at V1 was 8.91, and 
67.3 % of the subjects presented an inadequate glycemic 
control. These data are close to those of a large Brazilian 
multicenter study [8] in which 73 % of the patients with 
T2DM had an inadequate glycemic control (HbA1c >7 %). 
Another study carried out in Curitiba (Paraná) [40] had a 
quite low proportion of patients with T1DM and T2DM 
who reached all targets of good control recommended 
by the Brazilian Society of Diabetes regarding HbA1c 
levels, BP, BMI, and lipids, and the median HbA1c levels 
were 9.0 and 7.8  % in patients with T1DM and T2DM, 
respectively. Although this situation seems to be better 
in the U.S., an American study [10] has demonstrated 
that 47.8  % of the individuals with DM had an HbA1c 
level above 7  %. In Germany, a study [41] adopting an 
HbA1c below 6.5 % as a criterion of good control, found 
that 52.7 % of 5135 individuals with T2DM had an inad-
equate control. These data show a need, even in devel-
oped countries, for more effective measures to improve 
glycemic control and reduce complications associated 
with DM. In the present study, we observed a 0.69  % 
reduction in mean HbA1c from V1 to V4 (p =  0.0003) 
and 0.46 % from V1 to V5 (p = 0.0219). It is unclear why 
the glycemic control worsened from V4 to V5 (mean 
HbA1c increased in 0.24  % between these time points, 
p =  0.03), but it may have been influenced by intercur-
rent events during this period in some individuals, such 
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as hospital admissions, infections, emotional factors, or 
even a reduction in adherence to non-pharmacological 
treatment, such as diet errors and/or decrease in physi-
cal activity. The reduction in HbA1c level obtained with 
the intervention was more evident when we considered 
the group of 35 patients (67.3 %) with inadequate glyce-
mic control at two moments (3 months, p = 0.0001; and 
6 months, p = 0.0136). The same trend of improvement 
in glycemic control after the intervention was observed 
in individuals requiring an adjustment in pharmacologi-
cal treatment (63.5 %), who presented a 0.6 % reduction 
in mean HbA1c during 6 months of follow-up.
Education in DM is one of the most important factors 
to decrease the current high rates of poor glycemic con-
trol, particularly in Brazil. As already demonstrated in 
previous studies [10, 11, 37], cost-effectiveness is more 
favorable in adults with T2DM with educational pro-
grams conducted in groups, whereas in T1DM patients, 
improvements are more noticeable in psychosocial 
aspects [13]. The educational level certainly influences 
an individual’s capacity to grasp the content offered in 
educational programs. Even with the city of Maringá 
occupying the 23rd position on the Municipal Human 
Development Index (Índice de Desenvolvimento Humano 
Municipal, IDHM 2010) in Brazil [42], 59.6 % of the par-
ticipants in this study did not complete primary school, 
and only 9.6 % completed a higher education program.
A patient’s knowledge about his or her disease is one 
of the pillars to develop self-care actions. However, sim-
ple knowledge acquisition may not necessarily translate 
into behavior and lifestyle changes, but may enhance the 
capacity and confidence of the patient to develop self-
care actions, contributing to improve the management 
and prevention of chronic diseases such as DM.
The limitations of this study include the number of par-
ticipants, which is small considering all individuals with DM 
receiving primary health care in that municipality. In any 
event, the rate of follow-up loss after study enrollment was 
relatively low (14.8 %), which indicates that the individuals 
who took part in the study valued the proposed activities.
We should also mention as other limitations some fac-
tors inherent to this type of study, such as the duration 
of the intervention, since 6  months may not have been 
sufficient for the participants to translate the information 
into learned knowledge, and a limited ability to general-
ize the results of this type of study, so the estimates are 
only valid for a population with similar characteristics, 
although the sample was obtained at random. The fact 
that we adopted the Ames analyzer (Bayer Diagnostics, 
DCA 2000) as an instrument to evaluate the HbA1c level 
instead of the conventional HPLC method may also be 
a limitation. However, the choice to use the Ames ana-
lyzer emerged from a limitation of having the HbA1c 
tested at the public health system, which recommends 
that this test should only be performed at an interval of 
at least 6 months. We believe that this did not represent a 
problem in the interpretation of the results since there is 
a strong statistical correlation between the two methods, 
with a correlation coefficient of 0.95 [21], as observed in 
the present study (0.91).
Lastly, although the change of treatment regimen for 
some patients during the study may have represented a 
possible bias, this reinforces once again the need for a 
more effective follow-up of T2DM patients in primary 
care, including periodic evaluation of a specialist.
Despite these limitations, the results of this study indi-
cate a significant (p < 0.05) mean increase of 1.4 points in 
DM knowledge in patients with good glycemic control, and 
a decrease in mean HbA1c levels, BMI, and WC in some 
individuals. This signals the perspective of the actions of 
health professionals in reaching this type of population.
Conclusion
This study demonstrated an inadequate degree of knowl-
edge and satisfaction related to DM, and a high frequency 
of T2DM patients with inadequate glycemic control 
in primary care. The intervention of a mobile consul-
tancy specialized in DM adjusted the pharmacological 
treatment of 63.5 % of the patients and obtained partial 
improvement in blood glucose control, degree of knowl-
edge about DM, and satisfaction related to the disease, in 
addition to reducing the BMI and WC in some individu-
als. These findings indicate a need for more effective care 
and educational measures to decrease the complications 
and mortality related to the disease.
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